Divya Reddy, MD
Pulmonary Disease · Boston, MANPI 1588828370
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,048 of the $10,816 with a category attached, or 74.4%. Insmed, Inc. accounts for 98.7% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $10,579, more than ten times the $16 reported in 2020.
Across 27 payments — averaging $400.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$11K
- Bristol Myers Squibb$90
- Viatris Specialty LLC$35
- Bayer$14
Across 141 payments — averaging $2669.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$376K
What the payments were for
- Consulting fees$8,04874%
- Travel & lodging$2,37522%
- Food & beverage$3773%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 21 | $10,678 |
| Bristol Myers Squibb | 4 | $90 |
| Viatris Specialty LLC | 1 | $35 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$10,540
How this compares
$10,816 in reported general payments places this provider in the 85th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 15 | $196,382 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 156 | $136,791 |
| Incruse ElliptaUmeclidinium Bromide | 102 | $40,446 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $35,679 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,511 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $5,826 |
| Rifabutin | 17 | $5,266 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,257 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 170 | $4,764 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $1,968 |
| Fluticasone Propionate | 137 | $1,016 |
| Azithromycin | 54 | $968 |
| Ethambutol Hcl | 44 | $961 |
| Azelastine Hcl | 36 | $515 |
| Rifampin | 18 | $257 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.